Evidence for a Causal Role of Oxidative Stress in the Myocardial Complications of Insulin Resistance

Heart Lung and Circulation

Volumn 18, Issue 1, 2009, Pages 11-18

  Ritchie, Rebecca H ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; REACTIVE OXYGEN METABOLITE; RESVERATROL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; STILBENE; UBIDECARENONE; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; DIABETIC CARDIOMYOPATHY; DRUG EFFICACY; DRUG POTENCY; EVIDENCE BASED MEDICINE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RED WINE; WEIGHT REDUCTION; ANIMAL; DIABETES MELLITUS; HEART MUSCLE; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; CARDIOMYOPATHIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MYOCARDIUM; OXIDATIVE STRESS;

EID: 58949093581     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2008.11.003     Document Type: Article

References (98)

1. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
2. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
3. Jandeleit-Dahm K.A.M., Tikellis C., Reid C.M., Johnston C.I., and Cooper M.E. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23 (2005) 463-473
4. Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Lee E.T., Welty T.K., Fabsitz R.R., Robbins D., Rhoades E.R., and Howard B.V. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101 (2000) 2271-2276
5. Boudina S., and Abel E.D. Diabetic cardiomyopathy revisited. Circulation 115 (2007) 3213-3223
6. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., and Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30 (1972) 595-602
7. Ostenson C.G. The pathophysiology of type 2 diabetes mellitus: an overview. Acta Physiol Scand 171 (2001) 241-247
8. Witteles R.M., and Fowler M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51 (2008) 93-102
9. Novoa F.J., Boronat M., Saavedra P., Diaz-Cremades J.M., Varillas V.F., La Roche F., Alberiche M.P., and Carrillo A. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diabetes Care 28 (2005) 2388-2393
10. Sorescu D., and Griendling K.K. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8 (2002) 132-140
11. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271 (1996) C1424-C1437
12. Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med 41 (2006) 851-861
13. Mitchell J.B., Samuni A., Krishna M.C., DeGraff W.G., Ahn M.S., Samuni U., and Russo A. Biologically active metal-independent superoxide dismutase mimics. Biochemistry 29 (1990) 2802-2807
14. Selemidis S., Sobey C.G., Schmidt H.H.H.W., Wingler K., and Drummond G.R. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120 (2008) 254-291
15. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
16. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., and Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34 (2002) 379-388
17. Cave A., Grieve D., Johar S., Zhang M., and Shah A.M. NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology. Philos Trans R Soc Lond B Biol Sci 360 (2005) 2327-2334
18. Ritchie R.H., and Delbridge L.M.D. Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect?. Clin Exp Pharmacol Physiol 33 (2006) 171-178
19. Laskowski A., Woodman O.L., Cao A.H., Drummond G.R., Marshall T., Kaye D.M., and Ritchie R.H. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72 (2006) 112-123
20. Cooper S.A., Whaley-Connell A., Habibi J., Wei Y., Lastra G., Manrique C., Stas S., and Sowers J.R. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293 (2007) H2009-H2023
21. Dhalla A.K., Hill M.F., and Singal P.K. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 28 (1996) 506-514
22. Fang Z.Y., Prins J.B., and Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25 (2004) 543-567
23. Saraiva R.M., Duarte D.M., Duarte M.P.C., Martins A.F., Poltronieri A.V.G., Ferreira M.E., Silva M.C., Hohleuwerger R., Ellis A., Rachid M.B., Monteiro C.F.C., and Kaiser S.E. Tissue Doppler imaging identifies asymptomatic normotensive diabetics with diastolic dysfunction and reduced exercise tolerance. Echocardiography 22 (2005) 561-570
24. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 48 (2006) 548-555
25. Fang Z.Y., Najos-Valencia O., Leano R., and Marwick T.H. Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J Am Coll Cardiol 42 (2003) 611-617
26. van der Meer R.W., Diamant M., Westenberg J.J.M., Doornbos J., Bax J.J., de Roos A., and Lamb H.J. Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson 9 (2007) 645-651
27. Poirier P., Bogaty P., Garneau C., Marois L., and Dumesnil J.G. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24 (2001) 5-10
28. Zabalgoitia M., Ismaeil M.F., Anderson L., and Maklady F.A. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 87 (2001) 320-323
29. Di Bello V., Santini F., Di Cori A., Pucci A., Palagi C., Delle Donne M.G., Giannetti M., Talini E., Nardi C., Pedrizzetti G., Fierabracci P., Vitti P., Pinchera A., and Balbarini A. Relationship between preclinical abnormalities of global and regional left ventricular function and insulin resistance in severe obesity: a color Doppler imaging study. Int J Obes (Lond) 30 (2006) 948-956
30. Fischer M., Baessler A., Hense H.W., Hengstenberg C., Muscholl M., Holmer S., Doring A., Broeckel U., Riegger G., and Schunkert H. Prevalence of left ventricular diastolic dysfunction in the community-results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 24 (2003) 320-328
31. Watanabe K., Sekiya M., Tsuruoka T., Funada J., and Kameoka H. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. J Hypertens 17 (1999) 1153-1160
32. Zizek B., Poredos P., Trojar A., and Zeljko T. Diastolic dysfunction is associated with insulin resistance, but not with aldosterone level in normotensive offspring of hypertensive families. Cardiology 111 (2008) 8-15
33. Stewart K.J., Ouyang P., Bacher A.C., Lima S., and Shapiro E.P. Exercise effects on cardiac size and left ventricular diastolic function: relationships to changes in fitness, fatness, blood pressure and insulin resistance. Heart 92 (2006) 893-898
34. Hsu K.L., Tsai C.H., Chiang F.T., Lo H.M., Tseng C.D., Wang S.M., Chen C.F., and Tseng Y.Z. Myocardial mechanics and titin in experimental insulin-resistant rats. Jpn Heart J 38 (1997) 717-728
35. Huggins C.E., Domenighetti A.A., Ritchie M.E., Khalil N., Favaloro J.M., Proietto J., Smyth G.K., Pepe S., and Delbridge L.M.D. Functional and metabolic remodelling in GLUT4-deficient hearts confers hyper-responsiveness to substrate intervention. J Mol Cell Cardiol 44 (2008) 270-280
36. Severson D.L. Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes. Can J Physiol Pharmacol 82 (2004) 813-823
37. Davidoff A.J., Mason M.M., Davidson M.B., Carmody M.W., Hintz K.K., Wold L.E., Podolin D.A., and Ren J. Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab 286 (2004) E718-E724
38. Dutta K., Podolin D.A., Davidson M.B., and Davidoff A.J. Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 50 (2001) 1186-1192
39. Donthi R.V., Ye G., Wu C., McClain D.A., Lange A.J., and Epstein P.N. Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity. J Biol Chem 279 (2004) 48085-48090
40. Whaley-Connell A., Habibi J., Cooper S.A., Demarco V.G., Hayden M.R., Stump C.S., Link D., Ferrario C.M., and Sowers J.R. Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab 295 (2008) E103-E109
41. Whaley-Connell A., Govindarajan G., Habibi J., Hayden M.R., Cooper S.A., Wei Y., Ma L., Qazi M., Link D., Karuparthi P.R., Stump C., Ferrario C., and Sowers J.R. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab 293 (2007) E355-E363
42. Fulop N., Mason M.M., Dutta K., Wang P., Davidoff A.J., Marchase R.B., and Chatham J.C. Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart. Am J Physiol Cell Physiol 292 (2007) C1370-C1378
43. Wold L.E., Dutta K., Mason M.M., Ren J., Cala S.E., Schwanke M.L., and Davidoff A.J. Impaired SERCA function contributes to cardiomyocyte dysfunction in insulin resistant rats. J Mol Cell Cardiol 39 (2005) 297-307
44. Jordan J.E., Simandle S.A., Tulbert C.D., Busija D.W., and Miller A.W. Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther 307 (2003) 1007-1011
45. Elliott S.S., Keim N.L., Stern J.S., Teff K., and Havel P.J. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 76 (2002) 911-922
46. Rajasekar P., Palanisamy N., and Anuradha C.V. Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by l-carnitine: a study in the fructose-fed hypertensive rat. Clin Exp Hypertens 29 (2007) 517-530
47. Joyeux-Faure M., Rossini E., Ribuot C., and Faure P. Fructose-fed rat hearts are protected against ischemia-reperfusion injury. Exp Biol Med (Maywood) 231 (2006) 456-462
48. Delbosc S., Paizanis E., Magous R., Araiz C., Dimo T., Cristol J.-P., Cros G., and Azay J. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 179 (2005) 43-49
49. Al-Awwadi N.A., Bornet A., Azay J., Araiz C., Delbosc S., Cristol J.-P., Linck N., Cros G., and Teissedre P.-L. Red wine polyphenols alone or in association with ethanol prevent hypertension, cardiac hypertrophy, and production of reactive oxygen species in the insulin-resistant fructose-fed rat. J Agric Food Chem 52 (2004) 5593-5597
50. Xia Z., Kuo K.-H., Nagareddy P.R., Wang F., Guo Z., Guo T., Jiang J., and McNeill J.H. N-Acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 73 (2007) 770-782
51. Matsushima S., Kinugawa S., Ide T., Matsusaka H., Inoue N., Ohta Y., Yokota T., Sunagawa K., and Tsutsui H. Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 291 (2006) H2237-H2245
52. Hiranandani N., Bupha-Intr T., and Janssen P.M.L. SERCA overexpression reduces hydroxyl radical injury in murine myocardium. Am J Physiol Heart Circ Physiol 291 (2006) H3130-H3135
53. Ritchie R.H., Quinn J.M., Cao A.H., Drummond G.R., Kaye D.M., Favaloro J.M., Proietto J., and Delbridge L.M.D. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol 42 (2007) 1119-1128
54. 2+ release in cardiomyocytes by angiotensin II receptor blockade. Am J Physiol Heart Circ Physiol 292 (2007) H912-H920
55. Sakata S., Lebeche D., Sakata Y., Sakata N., Chemaly E.R., Liang L.F., Padmanabhan P., Konishi N., Takaki M., del Monte F., and Hajjar R.J. Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther 13 (2006) 987-996
56. 2+-ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats. J Physiol Biochem 62 (2006) 1-8
57. 2+ i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55 (2006) 608-615
58. Trost S.U., Belke D.D., Bluhm W.F., Meyer M., Swanson E., and Dillmann W.H. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51 (2002) 1166-1171
59. Lopaschuk G.D., Tahiliani A.G., Vadlamudi R.V., Katz S., and McNeill J.H. Cardiac sarcoplasmic reticulum function in insulin- or carnitine-treated diabetic rats. Am J Physiol 245 (1983) H969-H976
60. Li Q., Wu S., Li S.-Y., Lopez F.L., Du M., Kajstura J., Anversa P., and Ren J. Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage. Am J Physiol Heart Circ Physiol 292 (2007) H1398-H1403
61. Vasanji Z., Cantor E.J.F., Juric D., Moyen M., and Netticadan T. Alterations in cardiac contractile performance and sarcoplasmic reticulum function in sucrose-fed rats is associated with insulin resistance. Am J Physiol Cell Physiol 291 (2006) C772-C780
62. Xu S., Ying J., Jiang B., Guo W., Adachi T., Sharov V., Lazar H., Menzoian J., Knyushko T.V., Bigelow D., Schoneich C., and Cohen R.A. Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging. Am J Physiol Heart Circ Physiol 290 (2006) H2220-H2227
63. Adachi T., Weisbrod R.M., Pimentel D.R., Ying J., Sharov V.S., Schoneich C., and Cohen R.A. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 10 (2004) 1200-1207
64. Kowluru R.A., Engerman R.L., and Kern T.S. Diabetes-induced metabolic abnormalities in myocardium: effect of antioxidant therapy. Free Radic Res 32 (2000) 67-74
65. Cosenzi A., Bernobich E., Plazzotta N., Seculin P., Odoni G., and Bellini G. Lacidipine reduces high blood pressure and the target organ damage induced by high fructose diet in rats. J Hypertens 17 (1999) 965-971
66. Iyer S.N., and Katovich M.J. Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens 9 (1996) 662-668
67. Kamide K., Rakugi H., Higaki J., Okamura A., Nagai M., Moriguchi K., Ohishi M., Satoh N., Tuck M.L., and Ogihara T. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens 15 (2002) 66-71
68. Mizushige K., Yao L., Noma T., Kiyomoto H., Yu Y., Hosomi N., Ohmori K., and Matsuo H. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101 (2000) 899-907
69. Kaczmarczyk S.J., Andrikopoulos S., Favaloro J., Domenighetti A.A., Dunn A., Ernst M., Grail D., Fodero-Tavoletti M., Huggins C.E., Delbridge L.M., Zajac J.D., and Proietto J. Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy. J Mol Endocrinol 31 (2003) 449-459
70. Candido R., Forbes J.M., Thomas M.C., Thallas V., Dean R.G., Burns W.C., Tikellis C., Ritchie R.H., Twigg S.M., Cooper M.E., and Burrell L.M. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92 (2003) 785-792
71. Bendall J.K., Cave A.C., Heymes C., Gall N., and Shah A.M. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105 (2002) 293-296
72. Belke D.D., Larsen T.S., Gibbs E.M., and Severson D.L. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279 (2000) E1104-E1113
73. Finck B.N., and Kelly D.P. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 34 (2002) 1249-1257
74. How O.-J., Aasum E., Severson D.L., Chan W.Y.A., Essop M.F., and Larsen T.S. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55 (2006) 466-473
75. Rodrigo R., Guichard C., and Charles R. Clinical pharmacology and therapeutic use of antioxidant vitamins. Fundam Clin Pharmacol 21 (2007) 111-127
76. Macao L.B., Wilhelm Filho D., Pedrosa R.C., Pereira A., Backes P., Torres M.A., and Frode T.S. Antioxidant therapy attenuates oxidative stress in chronic cardiopathy associated with Chagas' disease. Int J Cardiol 123 (2007) 43-49
77. Lonn E., Yusuf S., Hoogwerf B., Pogue J., Yi Q.L., Zinman B., Bosch J., Dagenais G., Mann J.F.E., Gerstein H.C., and Investigators H. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes-results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25 (2002) 1919-1927
78. Munzel T., and Keaney J.F. Are ACE inhibitors a "magic bullet" against oxidative stress?. Circulation 104 (2001) 1571-1574
79. Lara-Padilla E., Kormanovski A., Grave P.A., Olivares-Corichi I.M., Santillan R.M., and Hicks J.J. Increased antioxidant capacity in healthy volunteers taking a mixture of oral antioxidants versus vitamin C or E supplementation. Adv Ther 24 (2007) 50-59
80. Upston J.M., Witting P.K., Brown A.J., Stocker R., and Keaney Jr. J.F. Effect of vitamin E on aortic lipid oxidation and intimal proliferation after arterial injury in cholesterol-fed rabbits. Free Radic Biol Med 31 (2001) 1245-1253
81. Wang X., Quinn P.J., and Vitamin. E and its function in membranes. Prog Lipid Res 38 (1999) 309-336
82. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S., and grp Ls. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
83. Goh S.S.C., Woodman O.L., Pepe S., Cao A.H., Qin C., and Ritchie R.H. The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid Redox Signal 9 (2007) 101-113
84. Hodgson J.M., and Watts G.F. Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. BioFactors 18 (2003) 129-136
85. Pirola L., and Frojdo S. Resveratrol: one molecule, many targets. IUBMB Life 60 (2008) 323-332
86. Hodgson J.M., Watts G.F., Playford D.A., Burke V., and Croft K.D. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 56 (2002) 1137-1142
87. Watts G.F., Playford D.A., Croft K.D., Ward N.C., Mori T.A., and Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 45 (2002) 420-426
88. Shephard R.J., and Balady G.J. Exercise as cardiovascular therapy. Circulation 99 (1999) 963-972
89. Sigal R.J., Kenny G.P., Wasserman D.H., Castaneda-Sceppa C., and White R.D. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 29 (2006) 1433-1438
90. Colberg S.R. Being active; a commentary. Diabetes Educucator 33 (2007) 989-990
91. Linke A., Adams V., Schulze P.C., Erbs S., Gielen S., Fiehn E., Mobius-Winkler S., Schubert A., Schuler G., and Hambrecht R. Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 111 (2005) 1763-1770
92. Brassard P., Legault S., Garneau C., Bogaty P., Dumesnil J.-G., and Poirier P. Normalization of diastolic dysfunction in type 2 diabetics after exercise training. Med Sci Sports Exerc 39 (2007) 1896-1901
93. Fossum E., Gleim G.W., Kjeldsen S.E., Kizer J.R., Julius S., Devereux R.B., Brady W.E., Hille D.A., Lyle P.A., and Dahlof B. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. J Intern Med 262 (2007) 439-448
94. Belardinelli R., Georgiou D., Ginzton L., Cianci G., and Purcaro A. Effects of moderate exercise training on thallium uptake and contractile response to low-dose dobutamine of dysfunctional myocardium in patients with ischemic cardiomyopathy. Circulation 97 (1998) 553-561
95. Powers S.K., Criswell D., Lawler J., Martin D., Lieu F.K., Ji L.L., and Herb R.A. Rigorous exercise training increases superoxide dismutase activity in ventricular myocardium. Am J Physiol 265 (1993) 193-201
96. Libonati J.R., Kendrick Z.V., and Houser S.R. Sprint training improves postischemic, left ventricular diastolic performance. J Appl Physiol 99 (2005) 2121-2127
97. Morris G.S., Baldwin K.M., Lash J.M., Hamlin R.L., and Sherman W.M. Exercise alters cardiac myosin isozyme distribution in obese Zucker and Wistar rats. J Appl Physiol 69 (1990) 380-383
98. McMullen J.R., Amirahmadi F., Woodcock E.A., Schinke-Braun M., Bouwman R.D., Hewitt K.A., Mollica J.P., Zhang L., Zhang Y., Shioi T., Buerger A., Izumo S., Jay P.Y., and Jennings G.L. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 104 (2007) 612-617